#ASCO21: Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone
With more and more PD-(L)1 checkpoint inhibitors flooding the market, there has been a long-running war over which of those drugs can secure a lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
